New trends in the development of AMPA receptor antagonists

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 8, 2004, Pages 1199-1213

  Gitto, Rosaria ^a   Barreca, Maria L ^a   De Luca, Laura ^a   Chimirri, Alba ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

AMPA receptor (AMPAR) antagonist; Glutamate

Indexed keywords

1,2 DIHYDRO 7 NITRO 2 OXO 6 [4 [(ARYLCARBAMOYLOXY)METHYL]IMIDAZOL 1 YL]QUINOLINECARBOXYLIC ACID DERIVATIVE; 2,3 QUINOXALINEDIONE DERIVATIVE; 4,5 DIHYDRO 8 NITRO 4 OXO 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 METHYL 5 (PIPERIDIN 1 YL METHYL) 7 NITRO 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 6 METHYL 5 (PYRROLIDIN 1 YL METHYL) 7 NITRO 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 2 (1H) OXOQUINOLINE 3 PHOSPHONIC ACID; 7 [3 [[( 4 CARBOXYPHENYL)AMINOCARBONYLAMINO]METHYL]PYRROL 1 YL] 6 CHLORO 3,4 DIHYDRO 3 OXOQUINOXALINE 2 CARBOXYLIC ACID; 7 NITRO 2 OXO 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID DERIVATIVE; 9 CARBOXYMETHYL 4 OXO 5H,10H IMIDAZO[1,2 A]INDENO[1,2 E]PYRAZIN 2 YL PHOSPHONIC ACID; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[(7 NITRO 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YLMETHYL) AMINO] METHYL] PHOSPHONIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; AMP 397A; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; GLUTAMATE RECEPTOR; GRA 293; IMIDAZOPYRAZINE DERIVATIVE; IONOTROPIC RECEPTOR ANTAGONIST; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RPR 117824; RPR 119990; S 176525; TQX 173; TRIPEPTIDE DERIVATIVE; UBP 275; UBP 277; UBP 279; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 202000;

AMYOTROPHIC LATERAL SCLEROSIS; BINDING SITE; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EYE DISEASE; GLIOBLASTOMA; HUMAN; MEDICAL LITERATURE; MENTAL DISEASE; MOLECULAR MODEL; MOOD DISORDER; MYOPIA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PATENT; PHARMACOPHORE; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; STROKE; STRUCTURE ACTIVITY RELATION; TINNITUS;

EID: 4344627088     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.8.1199     Document Type: Review

References (77)

1. DINGLEDINE R, BORGES K, BOWIE D, TRAYNELIS SF: The glutamate receptor ion channels. Pharmacol. Rev. (1999) 51(1):7-61.
2. JINGAMI H, NAKANISHI S, MORIKAWA K: Structure of the metabotropic glutamate receptor. Curr. Opin. Neurobiol. (2003) 13(3):271-278.
3. LEES GJ: Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs (2000) 59 (1):33-78.
4. STONE TW, ADDAE JI: The pharmacological manipulation of glutamate receptors and neuroprotection. Eur. J. Pharmacol. (2002) 447(2-3):285-296.
5. ROSENMUND C, STERN-BACH Y, STEVENS CF: The tetrameric structure of a glutamate receptor channel. Science (1998) 280(5369):1596-1599.
6. SUTCLIFFE MJ, WO ZG, OSWALD RE: Three-dimensional models of non-NMDA glutamate receptors. Biophys. J. (1996) 70(4):1575-1589.
7. SUTCLIFFE MJ, SMEETON AH, WO ZG, OSWALD RE: Three-dimensional models of glutamate receptors. Biochem. Soc. Trans. (1998) 26(3):450-458.
8. HOGNER A, GREENWOOD JR, LILJEFORS T et al.: Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem. (2003) 46(2):214-221.
9. ARMSTRONG N, GOUAUX E: Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron (2000) 28(1):165-181.
10. CHIMIRRI A, GITTO R, ZAPPALA M: AMPA receptor antagonists. Expert Opin. Ther. Patents (1999) 9(5):557-570.
11. CORDI AA, DESOS P, RUANO E et al.: Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity. Farmaco, (2002) 57(10):787-802.
12. NAKANO M, UEDA H, LI JY, MATSUMOTO M, YANAGIHARA T A potent AMPA/kainate receptor antagonist, YM-90K, attenuates the loss of N-acetylaspartate in the hippocampal CA1 area after transient unilateral forebrain ischemia in gerbils. Life Sci. (2001) 69(17):1983-1990.
13. NIKAM SS, KORNBERG BE: AMPA receptor antagonists. Curr. Med. Chem. (2001) 8(2):155-170.
14. TURSKI L, HUTH A, SHEARDOWN M et al.: ZK-200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc. Natl. Acad. Sci. USA (1998) 95(18):10960-10965.
15. ELTING JW SULTER GA, KASTE M et al.: AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke (2002) 33(12):2813-2818.
16. TURSKI L, SCHNEIDER HH, NEUHAUS R et al.: Phosphonate quinoxalinedione AMPA antagonists. Restor. Neurol. Neurosci. (2000) 17(1):45-59.
17. TAKANO Y, SHIGA F, ASANO J, ANDO N, UCHIKI H, ANRAKU T Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. Bioorg. Med Chem. Lett(2003) 13(20):3521-3525.
18. VARANO F, CATARZI D, COLOTTA V et al.: Synthesis, glycine/NMDA and AMPA binding activity of some new 2,5,6-trioxopyrazino[1,2,3-de]quinoxalines and of their restricted analogs 2,5-dioxo- and 4,5-(dioxoimidazo[1,5,4-de]quinoxalines.Arch. Pharm. (Weinheim) (1999) 332(6):201-207.
19. CATARZI D, COLOTTA V, VARANO F et al: 7-Chloro-4,5-dihydro,-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[l, 5-a]quinoxaline-2-carboxylates as novel highly selective AMPA receptor antagonists. J. Med. Chem. (2000) 43(21):3824-3826.
20. CATARZI D, COLOTTA V, VARANO F et al.: Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo [1,5-a]quinoxaline-2-carboxylates analogues of TQX-173. J. Med. Chem. (2001) 44 (19):3157-3165.
21. CATARZI D, COLOTTA V, VARANO F et al.: Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline- 2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists. J. Med. Chem. (2004) 47(1):262-272.
22. VARANO F, CATARZI D, COLOTTA V et al.: Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazoline-2-carboxylates as novel excitatory amino acid antagonists. J. Med. Chem. (2002) 45(5):1035-1044.
23. COLOTTA V, CATARZI D, VARANO F et al.: 3-Hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg. Med. Chem. Lett (2004) 14(9):2345-2349.
24. MIGNANI S, BOHME GA, BOIREAU A et al.: 8-Methylureido-4, 5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e] pyrazines: highly potent in vivo AMPA antagonists. Bioorg. Med. Chem. Lett. (2000) 10(6):591-596.
25. STUTZMANN JM, BOHME GA, BOIREAU A et al.: 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg. Med. Chem. Lett. (2000) 10(10):1133-1137.
26. JIMONET P, CHEVE M, BOHME GA et al.: 8-Methylureido- 10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonists. Bioorg. Med. Chem. (2000) 8(8):2211-2217.
27. PRATT J, JIMONET P, BOHME GA et al.: Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and-9-carboxylic (acetic) acid AMPA antagonists. Bioorg. Med. Chem. Lett (2000) 10(24):2749-2754.
28. JIMONET P, BOHME GA, BOUQUEREL J et al.: Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin- 2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. Bioorg. Med. Chem. Lett. (2001) 11(2):127-132.
29. STUTZMANN JM, BOHME GA, BOIREAU A et al.: Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives. Bioorg. Med. Chem. Lett (2001) 11(9):1205-1210.
30. MIGNANI S, BOHME GA, BIRRAUX G et al.: 9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2- carboxyl ic acid (RPR-117824): selective anticonvulsive and neuroprotective AMPA antagonist. Bioorg. Med. Chem. (2002) 10(5):1627-1637.
31. MORE JC, TROOP HM, DOLMAN NP, JANE DE: Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br. J. Pharmacol. (2003) 138(6):1093-1100
32. 2+ permeability and joro spider toxin sensitivity of AMPA and kainate receptors on cerebellar granule cells. Eur. J. Pharmacol. (1998) 351(1):131-138.
33. 2+-Permeable AMPA receptors in cultured rat hippocampal neurons. Neurosci. Res. (1997) 29(1):27-36.
34. 2+-permeable AMPA receptor antagonist activity. Bioorg. Med. Chem. Lett (2001) 11(10):1261-1264
35. 2+-permeable AMPA receptor antagonists. Bioorg. Med. Chem. Lett (2001) 11(19):2663-2666.
36. 2+-permeable AMPA receptor antagonists. Bioorg. Med. Chem. (2002) 10(5):1347-1359.
37. 2+-permeable AMPA receptors. J. Med. Chem. (2002) 45(26):5745-5754.
38. DONEVAN SD, ROGAWSKI MA: GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron (1993) 10(1):51-59.
39. DONEVAN SD, YAMAGUCHI S, ROGAWSKI MA: Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther (1994) 271(1):25-29.
40. ANDRÁSI F: Talampanel. Antiepileptic, neuroprotectant, skeletal muscle relaxant. Drugs Fut. (2001) 26(8):754-756.
41. RUEL J, GUITTON MJ, PUELL JL: Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-2 competitive AMPA antagonist. CNS Drug Rev. (2002) 8(3):235-254.
42. SZABADOS T, GIGLER G, GACSALYI I, GYERTYAN I, LEVAY G: Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GM 52466, GYKI 53405, and GYKI 53655. Brain Res. Bull. (2001) 55(3):387-391.
43. VILAGI I, TAKACS J, GULYAS-KOVACS A, BANCZEROWSKI-PELYHE I, TARNAWA I: Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. (2002) 59(1):35-40.
44. BEVACQUA F, BASSO A, GITTO R, BRADLEY M, CHIMIRRI A: Solid-phase Friedel-Crafts acylation on polystyrene resins-synthesis of antiepiletic 1-aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones. Tetrahedron Lett. (2001) 42(43):7683-7685.
45. HAMORI T, SOLYOM S, BERZSENYI P, ANDRASI F, TARNAWA I: Structural analogues of some highly active non-competitive AMPA antagonists. Bioorg. Med. Chem. Lett. (2000) 10(9):899-902.
46. GITTO R, ZAPPAL M, DE SG, CHIMIRRI A: Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. Farmaco (2002) 57(2):129-134.
47. SOLYOM S: Research on new AMPA antagonists of 2,3-benzodiazepine type. Pharmazie (2001) 56(Suppl.1)S62-66.
48. GRASSO S, DE SARRO G, DE SARRO A et al.: Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin- 4-ones. Bioorg. Med. Chem. Lett (2001) 11(4):463-466.
49. DE SARRO G, CHIMIRRI A, MELDRUM BS: Group III mGlu receptor agonists potentiate the anticonvulsant effect of AMPA and NMDA receptor block. Eur. J. Pharmacol. (2002) 451(1):55-61.
50. ABRAHAM G, SOLYOM S, CSUZDI E et a;.: New non competitive AMPA antagonists. Bioorg. Med. Chem. (2000) 8(8):2127-2143.
51. ZAPPALA M, GITTO R, BEVACQUA F et al.: Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem. (2000) 43(25):4834-4839.
52. CHIMIRRI A, GITTO R, QUARTARONE S, ORLANDO V, DE SARRO A, DE SARRO GB: Synthesis and pharmacological properties of new 3-ethoxycarbonyl-11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepines. Farmaco (2002) 57(9):759-763.
53. GITTO R, ORLANDO V, QUARTARONE S et al.: Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem. (2003) 46(17):3758-3761.
54. RZESKI W, IKONOMIDOU C, TURSKI L: Glutamate antagonists limit rumor growth. Biochem. Pharmacol. (2002) 64(8):1195-1200.
55. PEI XF, STURGESS MA, VALENZUELA CF, MACCECCHINI ML: Allosteric modulators of the AMPA receptor: novel 6-substituted dihydrophthalazines. Bioorg. Med. Chem. Lett. (1999) 9(4):539-542.
56. PELLETIER JC, HESSON DP, JONES KA, COSTA AM: Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. (1996) 39(2):343-346.
57. LI BQ PEI XF, MACCECCHINI M: Novel sulfur containing dihydrophthalazine antagonists of AMPA receptors. 220th ACS Meeting. Washington DC, USA (2000) MEDI 212.
58. GITTO R, CHIMIRRI A, ZAPPALA M, DE SARRO G, DE SARRO, A. Synthesis and pharmacological evaluation of 4-aryl-6,7-dimethoxyphthalazines as anticonvulsant agents. Med. Chem. Res. (2000) 10(1):1-10.
59. GRASSO S, DE SARRO G, DE SARRO A et al.: Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones. J. Med. Chem. (2000) 43 (15):2851-2859.
60. CHENARD BL, WELCH WM, BLAKE JF et al.: Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether. J. Med. Chem. (2001) 44(11):1710-1717.
61. CHENARD BL, MENNITI FS, PAGNOZZI MJ, SHENK KD, EWING FE, WELCH VIM: Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10(11):1203-1205.
62. MENNITI FS, BUCHAN AM, CHENARD BL et al.: CP-465,022, a selective noncompetitive AM PA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke (2003) 34(1):171-176.
63. LAZZARO JT, PATERNAIN AV, LERMA J et al.: Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology (2002) 42(2):143-153.
64. WELCH WM, EWING FE, HUANG J et al.: Atropisomeric quinazolin-4-one derivatives are potent noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists. Bioorg. Med Chem. Lett (2001) 11 (2):177-181.
65. MENNITI FS, CHENARD BL, COLLINS MB et al.: Characterization of the binding site for a novel class of noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists. Mol. Pharmacol. (2000) 58(6):1310-1317.
66. OHNO K, TSUTSUMI R, MATSUMOTO N et al.: Functional characterization of YM928, a novel moncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. J. Pharmacol. Exp. Ther. (2003) 306 (1):66-72.
67. YAMASHITA H, OHNO K, AMADA Y et al.: Effects of 2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3- thiazin-4-one (YM928), an orally active α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J. Pharmacol. Exp. Ther. (2004) 308(1):127-133.
68. FEIGIN V: Irampanel Boehringer Ingelheim. Curr. Opin. Investig. Drugs (2002) 3(6):908-910.
69. + channels. Br. J. Pharmacol. (2001) 133(6):789-796.
70. + channel blocker BIIR-561 CL is protective in a model of global cerebral ischaemia. Eur. J. Pharmacol. (2001) 421(3):165-170.
71. GITTO R, BARRECA ML, DE LUCA L et al.: Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist. J. Med. Chem. (2003) 46(1):197-200.
72. GITTO R, CARUSO R, ORLANDO V et al.: Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives. Farmaco (2004) 59(1):7-12.
73. FERRERI G, CHIMIRRI A, RUSSO E et al.: Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents. Pharmacol. Biochem. Behav. (2004) 77(1):85-94.
74. DE LUCA L, MACCHIARULO A, COSTANTINO G et al.: Binding modes of noncompetitive AMPA antagonists: a computational approach. Farmaco (2003) 58(2):107-113.
75. BARRECA ML, GITTO R, QUARTARONE S, DE LUCA L, DE SARRO G, CHIMIRRI A. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. J. Chem. Inf. Comput. Sci. (2003) 43(2):651-655.
76. MACCHIARULO A, DE LUCA L, COSTANTINO G et al.: QSAR study of anticonvulsant negative allosteric modulators of the AMPA receptor. J. Med. Chem. (2004) 47(7):1860-1863.
77. JACKSON A, MEAD AN, STEPHENS DN: Behavioural effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate-receptor antagonists and their relevance to substance abuse. Pharmacol. Ther. (2000) 88(1):59-76.